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As I related in recent e-mails to staff, I have been asked to serve as Acting Director, 
Division of HIV/AIDS Prevention (DHAP), until they identify a permanent Director. With 
some reluctance, I have agreed to work in this capacity on a time-limited basis, starting 
August 19. I have recommended to Center leadership that Dr. Phil LoBue serve as 
interim DTBE Director while I am on TDY.  
 
It is with profound sadness that I report the passing of two former TB public health 
advisors, Louis Salinas and Bertrand W. Russell. Although they both left DTBE some 
time ago, many of you may remember them, especially those of you in the field. Please 
see the In Memoriam section of this issue to read about their important contributions 
and accomplishments. 
 
As many of you know, CDC grantees received a letter in March from CDC’s 
Procurement and Grants Office, stating that a series of spending cuts will cancel 
approximately $85 billion in budgetary resources across the federal government for the 
remainder of the federal fiscal year. Because of these cuts, very difficult decisions are 
being made regarding staffing and program activities. Shortages of TB drugs and 
diagnostics have also hindered TB program work. Yet in the face of these challenges, 
the U.S. TB case count is under 10,000 for the first time ever. I appreciate that you are 
maintaining your resilience and remaining focused on the work that needs to be done. 
 
The Federal TB Task Force (TBTF) met in Bethesda, Maryland, on April 8. The TBTF is 
a coalition of federal agencies involved in U.S. TB research and control efforts. It 
facilitates coordination of activities among these agencies. Dr. Christine Sizemore of the 
National Institutes of Health (NIH) and I currently serve as co-chairs. At this meeting, a 
major topic of discussion was the shortage of TB drugs and diagnostic products. We 
shared updates regarding our efforts, in collaboration with the Food and Drug 
Administration (FDA), to find ways to address these shortages. 
 
There is now some good news: isoniazid is available again. The shortage of PPD 
tuberculin solutions is being resolved as well. The supply of Aplisol (JPH 
Pharmaceuticals) is normal and stable, and the supply of Tubersol (Sanofi) is back to 
normal, although the distribution chains have not been restored fully. A link to the FDA 





The 62nd conference of the Epidemic Intelligence Service (EIS) was held April 22–26, 
2013, in Atlanta. This conference is an annual scientific meeting for the national and 
international public health community. At the conference, EIS officers present 
investigation findings, epidemiologists discuss current topics, presentations highlight 
CDC’s epidemiologic activities, public health professionals network and share ideas, 
and CDC programs recruit new EIS officers. Please see the summary in this issue 
about the TB-related presentations given this year. 
 
The Advisory Council for the Elimination of Tuberculosis (ACET) met in Atlanta June 4 
and 5. I shared DTBE’s proposed strategic vision, which has three components: retain 
our optimistic goal of eventual TB elimination in the U.S.; bridge the current gaps in 
implementation, knowledge, and ambition; and focus our activities so as to address 
challenges and opportunities. Dr. Jon Warkentin suggested that it is time to update the 
joint CDC/ACET document, Essential Components of a Tuberculosis Prevention and 
Control Program, http://www.cdc.gov/MMWR/preview/MMWRhtml/00038823.htm. Dr. 
Christine Ho gave an update on the Affordable Care Act (ACA), reminding us that 
guarantees for inherently governmental public health services were not the goal of the 
ACA, and that expansion of the ACA will not really decrease the need for CDC and 
health department partners to provide these critical services. We also discussed drug 
and diagnostics shortages. Presenting the field perspective, Dr. Jennifer Flood 
suggested that DTBE consider forming a team dedicated to addressing drug supply 
issues as one way to prevent shortages in the future. Providing the CDC perspective, 
Dr. Sundari Mase noted that shortages are most often caused by manufacturing issues. 
Possible proactive solutions include creating a TB drug repository, as well as working 
with the HHS repository to stockpile TB drugs. We also heard updates on TB in 
correctional settings, in homeless populations, and in persons residing along the 
US/Mexico border. These populations have multiple and complex risk factors, 
contributing to increased rates of TB in these groups. We need to continue to look for 
opportunities to partner with others to reduce TB in these hard-hit groups. The next 
ACET meeting is planned for December 3-4, 2013.  
 
The 2013 National TB Conference was held in Atlanta from June 11 to 13, 2013. In this 
issue, we have included information on the winners of the annual poster competition as 
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HIGHLIGHTS FROM STATE AND 
LOCAL PROGRAMS 
 
2012 New England TB Heroes Awards 
Presented to TB Case Manager and 
Lab Supervisor; First Lifetime TB 
Achievement Award Given 
 
The annual New England TB Heroes Award 
recognizes extraordinary contributions to the care 
or management of patients infected with M. 
tuberculosis complex or an activity that greatly 
enhanced the TB prevention and control efforts in 
a locality or state. The 2012 awards were 
bestowed on Danielle Orcutt, an epidemiologist-
case manager with the Connecticut Department 
of Public Health TB Control Program, and Julie 
Crosby, supervisor of the mycobacterial 
laboratory at the Maine Center for Disease 
Control and Prevention. Additionally, the first 
Lifetime TB Achievement award was given to 
Sue Etkind, recently retired Director of the 
Massachusetts TB Control Program and current 
Director of Stop TB USA. 
TB Hero Danielle Orcutt (center), Margaret Tate (left), and 
Maureen Williams, RN (right) 
 
Danielle Orcutt had multiple nominators who 
spoke eloquently of her initiative, organization, 
cheerfulness, support, and encouragement to 
local health staff, and dedication to the control of 
TB in Connecticut. As one person summarized 
these qualities, “Danielle goes the extra mile in 
TB.” The nomination statement highlighted 
Danielle’s knowledge, motivation, and dedication 
to the care of persons with TB. 
 
The selection committee was impressed by the 
description of Danielle as always being 
"available, regardless of her present workload” 
and her “unwavering willingness to help us on 
any level" so that each patient receives the best 
of care. 
 
Testimony of Danielle’s contributions also came 
from the field: “We consider her a coworker at the 
local level. She has the uncanny ability to move 
between roles of enforcer, diplomat, and 
empathizer, depending on the complexity of the 
situation.” 
Julie Crosby (right) holds award presented by Dalit Wolfe, 
RN, BSN, Maine TB coordinator 
 
Julie Crosby is the supervisor for the 
TB/Mycology/Rabies lab for the State of Maine’s 
Health and Environmental Testing Laboratory. 
She has been at this lab for more than 30 years. 
Julie plays a vital and active role in identifying M. 
tuberculosis complex, performing drug 
susceptibility testing, and sending specimens for
TB 
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 genotyping. Julie’s team in the TB lab has taken 
her lead and is as dedicated, friendly, and 
committed as she is. Julie and her staff train TB 
public health nurses on specimen collection, 
mandatory demographic data, specimen volume, 
and other critical information to assist in 
specimen handling and results interpretation. The 
TB Epidemiologist remarked, “Julie’s quick 
response time and willingness to stay on top of 
things is critical. She is eager to be part of the 
process and understand the whole picture.”  
 
Julie is known in TB control for always going the 
extra mile to ensure patients receive the most 
timely diagnosis. She can be counted on to take 
the time to answer questions, no matter how 
busy she is. Julie is dedicated to giving lab tours 
and is eager to explain the processes for TB 
testing to anyone who wishes to learn more. 
Maine’s TB Controller states, “Maine TB Control, 
our TB patients, and the general public are 
thankful for the vital work Julie and her team do.” 
Bob Carr, MA Bureau of Infectious Disease, Deputy 
Director, praises Sue Etkind, Exec Director, Stop TB USA 
 
The New England TB Consortium was inspired to 
give the first Lifetime TB Achievement Award to 
Sue Etkind, R.N. Sue has long been a leader in 
TB control and public health in Massachusetts, 
New England, and the United States. 
 
Over the years, Sue has demonstrated her 
outstanding leadership as an exemplary program 
manager, a noted researcher, and a dedicated 
public servant. As Director of the Massachusetts 
Division of Tuberculosis Prevention and Control 
since 1984, she displayed courage in responding 
to the resurgence of TB in the late 1980s and 
early 1990s, determination in the face of financial 
cutbacks, dedication in turning the tide of 
increasing TB cases, and vision for what the 
future holds for the ever-changing requirements 
of effective TB prevention and control. Sue is an 
untiring advocate for public health and has never 
let obstacles like uncertain funding prevent her 
from embarking on a great idea. She is highly 
respected by her colleagues and staff, many of 
whom have been beneficiaries of her mentoring.  
 
—Reported by Dalit Wolfe, RN, BSN, MPH 
Coordinator, ME TB Control Program; 
Lynn Sosa, MD 
CT Deputy State Epidemiologist; 
Jennifer Cochran, MPH, 
Dir, MA Div of TB Prevention and Control; and 
Mark Lobato, MD, CDC Regional Medical Officer 
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Past recipients of the TB Heroes Award 
2008 
Suzanne Gunston, RN; Maine TB Program manager 
(retired) 
Susan Nutini, RN; RISE TB Clinic, RI 
2009 
Florence Grant, RN; Public Health Nurse, City of 
Cambridge, MA 
Helen Wu;  Bridgeport, Connecticut TB outreach staff 
2010 
Jeanne Ellis, RN; Getchell TB Clinic, Worcester, MA 
Alex Sloutsky, PhD; University of Mass. Laboratory 
and former director Mass. State Mycobacteriology 
Lab 
2011 
Maureen Williams, RN; nurse consultant Connecticut 
TB Program 
Nancy O’Neil, LPN; Veterans Affairs Boston 
Healthcare System 
 
New York City’s First TB Walk 
Reprinted with permission from the Spring 2013 issue of 
the Northeastern Spotlight newsletter. 
The New York City Department of Health and 
Mental Hygiene (NY City DOHMH) Bureau of 
Tuberculosis Control, with the New Jersey 
Medical School Global Tuberculosis Institute and 
others, sponsored the first Annual New York City 
World TB Day Walk on Saturday, March 23. Over 
100 people participated in this awareness-raising 
walk from Union Square to Washington Square. 
 
This was followed by a performance by the New 
York Stars Twirling and Marching Band, Inc., as 
walkers entered the educational rally. The 
diverse roster of speakers included Dr. Joseph 
Burzynski, Assistant Commissioner at the NY 
City DOHMH Bureau of TB Control; TB survivors 
Jigna Rao, Bart Willems, and Patricia Bond; as 
well as New York City Council Member Dr. 
Mathieu Eugene. The NY City DOHMH and 
community organizations provided educational 
materials and information on accessing 
community resources. This event united a 
diverse group of community stakeholders to build 
partnerships, educate the community, and raise 
awareness that TB is still a prominent health 
issue in NY City and around the world. 
 
Participants in the NYC World TB Day Walk going through 
Washington Square Park. 
—Reported by DJ McCabe, RN, MSN 
New Jersey Medical School 
Global Tuberculosis Institute 
 
Texas’s “Stop TB in My Lifetime” 
5K Fun Run/Walk and 
TB Update Training 
 
The Heartland National TB Center hosted a TB 
Update training and Stop TB in My Lifetime 5K 
Fun Run/Walk event on March 22, 2013, in 
observance of World TB Day. The event took 
place on the grounds of the Texas Center for 
Infectious Disease (TCID).   
 
The overarching goal of the event was to bring 
TB awareness to the community, highlight patient 
struggles, and foster cooperation between 
various TB entities in the community.  The event 
encompassed those who wished to participate 
from the TCID (including patients); two TB Trials 
Consortium (TBTC) sites, San Antonio and 
Houston; local and regional health offices; the 
San Antonio Metropolitan Health District; HIV 
groups; local hospitals; and others with an 
interest in TB.  
 
The day began with a TB Update training session 
(for which CNEs and CMEs were available) 
consisting of the following presentations. These 




were presented live (to 71 participants), as well 
as by webcast (to 78 participants):  
 
• Co-morbidities in Substance Abuse That 
Impact Management of TB, by Lisa Armitige, 
MD, PhD; Heartland National TB Center 
• Interferon Gamma Release Assays: 
Understanding the Test by David Griffith, 
MD; Heartland National TB Center 
• Update from CDC’s Tuberculosis Trials 
Consortium by Marc Weiner, MD, University 
of Texas Health Science Center, San 
Antonio 
• Implementation of the 12-Dose Regimen: A 
State Perspective by Phil Griffin; Kansas 
Department of Health and Environment 
• Laboratory Update by Denise Dunbar; Texas 
Department of State Health Services 
• Ethical Considerations in the TB Patient 
(approved for one-hour of ethics credit) by 
Eva Moya, PhD, LMSW; the University of 




the TB Update 





that event featured a proclamation that was 
signed by Mayor Julian Castro of the City of San 
Antonio and read by Vincent Nathan, Ph.D., 
MPH, Assistant Director for Environmental 
Safety, City of San Antonio. This was followed by 
the singing of the national anthem by a Heartland 








The race was 
officially 
started by the Texas TB Program Manager. The 
route through the TCID/State Hospital grounds 
accommodated 192 runners/ walkers, 30 of 
whom were patients at TCID. Each participant 
received a t-shirt, “goodie” bag, and lunch. A live 
band (members of the TCID staff and patients) 
played for the crowd as attendees enjoyed lunch 
and networked with each other. The patients 
were involved in assisting with the event as well 
as participating in the run/walk, and took pride in 
their efforts.  
 
Vendor booths 
were set up 
around the TCID 





participated as vendors at the event: 
 
• Baptist Health System 
• City of San Antonio Metropolitan Health 
District 
• City of San Antonio 
• San Antonio Aids Foundation 
• Stop TB Partnership 
• Texas Dept of State Health Services, Region 
8 Office 
• The American Lung Association 
• The American Diabetes Association 
• The University of Texas at El Paso 
 
 




And the following offered support to the events 
via donations of items or donation of staffing: 
 
B & B LLC (Burger King and Wahoos Tacos 
Franchise) ● Balloon Productions ● Baylor 
College of Medicine ● Chobani Yogurt ● 
Community Research Advisory Group-Treatment 
Action Group ● Home Depot ● Houston 
Department of Health and Human Services ● 
Kansas Department of Health and Environment 
● La Perla Mexican Restaurant ● Robes St. 
Juste Company (Burger King Franchise) ● Texas 
Center for Infectious Disease ● TCID Volunteer 
Service Council ● Texas Dept of State Health 
Services ● The Texas Ski Ranch ● UT Health 
Northeast ● Walker Advertising. 
 
—Reported by Sam Caballero, MA  
Director of Education & Training 
Heartland National TB Center 
 
2013 EIS Conference 
The 2013 Epidemic Intelligence Service (EIS) 
Conference, held April 22 to 26 this year, again 
featured a session on TB. Three of the EIS 
officers from DTBE’s International Research and 
Programs Branch (IRPB) were featured during 
the session. Dr. Sara Auld presented “Negative 
Tuberculin Skin Test Result and Increased Risk 
of Death — United States, 1993–2008”; Dr. 
Chimmeremma Nnadi presented “Enlarged 
Peripheral Lymph Nodes and Positive 
Mycobacterium tuberculosis Culture among 
People Living with HIV — Cambodia, Thailand, 
and Vietnam, September 2006–July 2008”; and 
Dr. Terrence Lo presented “Drinking, 
Bootlegging, and an Outbreak of Drug-Resistant 
Tuberculosis — Rural Kentucky, 2007–2012.” 
A fourth presentation entitled “Relationship 
between Cigarette Smoking and Secondhand 
Smoke Exposure and Latent Tuberculosis 
Infection Among US Adults, National Health and 
Nutrition Examination Survey, 1999–2000” was 
given by Dr. Eugene Lam from the Global 
Immunization Division in the Center for Global 
Health. In addition, Dr. Courtney Yuen from 
DTBE’s Surveillance, Epidemiology, and 
Outbreak Investigation Branch presented 
“Predicting Year of Tuberculosis Elimination 
Among U.S.-born Populations, by State” in the 
“Money, Math, and Modeling” session on 
Thursday. All the presentations were well-
received and generated enthusiastic responses 
and discussions. 
 
DTBE also had very successful matches this 
year. Two new EIS officers are coming into IRPB: 
Aditya Sharma, MD, and Tyson Volkmann, PhD. 
One new officer is coming into SEOIB: Eric 
Reaves, DO. We are looking forward to working 
with these new officers. 
 
—Reported by Sean Cavanaugh, MD 
Div of TB Elimination 
 
Winners of 2013 National TB 
Conference Awards 
 
2013 NTCA Special Awards 
 
In 2010, the National TB Controllers Association 
(NTCA) began recognizing colleagues in the field 
of TB control for their outstanding contributions. 
These awards are presented at the annual 
National TB Conference by the President of the 
NTCA. This year’s President, Dr. Jon Warkentin, 
presented the following awards during the June 
2013 conference. 
 
TB Controller of the Year 
This is the National Tuberculosis Controller’s 
highest award. It recognizes an outstanding 
contribution and impact on tuberculosis 
prevention and control at the local, state, 




regional, or national level. The award recognizes 
what TB controllers are all about. The winner of 
this award was Dr. Naveen Patil of the 
Arkansas Department of Health. Dr. Patil was 
not at the conference to accept the award. 
 
William Stead TB Clinician Award 
This award recognizes outstanding 
commitment and performance by a 
clinician providing tuberculosis 
care, leadership, or mentoring. This 
was presented to Dr. Gisela 
Schecter of the California 
Department of Public Health, 
shown here. 
 
Carol Pozsik TB Nurse Award 
This award honors 
exemplary care, 
service, dedication, 
or leadership in the 
field of TB nursing. 
Presented to Maria 
Dalbey of the 
Kentucky 
Department of Public Health’s TB Program, 




This award honors 
exemplary service, 
dedication, or 
leadership to a TB 
laboratory 
professional. The 
award was presented 
to Julie Tans-






Charles DeGraw Advocacy Award 
This award recognizes an individual who has 
made an outstanding effort or achievement in 
advocating for increased support and recognition 
of TB control and prevention efforts. The winner 
of this award was Dr. Ana Lopez-Defede of the 
University of South Carolina; she was not at 
the conference so unable to accept the award. 
 
Joe Ware Partner Service Award 
This award recognizes the community partner 
who has made an outstanding effort to support 
TB programs in their provision of services and 
the protection of the public’s health. The award 
was won by the Hawthorne Pharmacy, South 
Carolina. The pharmacy did not have a 






recognizes a CDC 
employee who has 
provided 
outstanding support, through partnership with a 
state or local tuberculosis community, in the 
interest of tuberculosis control and prevention. 
Presented to Phil Talboy, DTBE, above right 




This award, given at 
the discretion of the 
President, recognizes 
the individual who, in 
the President’s 
opinion, exemplifies 
service and dedication 
to TB control efforts. 
This was presented to 
John Seggerson, 
DTBE (ret.) shown 
here, and Stop TB USA.  
 
 




2013 Poster Competition 
 
This year, the National TB Conference held its 8th 
annual poster competition; of 55 posters 
developed and submitted by TB program staff 
throughout the country, 48 were available for 
judging and viewing during the conference. A 
panel of judges reviewed and rated the posters 
based on three criteria areas: 
 
Relevance to TB control or elimination: 
Topic provides information that can potentially be 
transferred to another program; addresses or 
identifies high-priority area of TB program or 
problematic area; provides strategy for better use 
of resources. 
 
Clarity of information: 
Information is written clearly, in short sentences, 
with bulleted points to enhance readability; 
adequate amount of information is provided to 
explain project, but not a complete journal article 
posted on the wall! 
 
Graphic presentation: 
Graphics are used to clearly present information 
(photographs to demonstrate or model, graphs 
and charts to display data); graphics are 
appealing to the viewer (not crowded, and colors 
are used appropriately). 
 
The poster judges for this year were Zelalem 
Temesgen (Mayo RTMCC), Jason Cummins 
(Tennessee), John Jereb (CDC), Judy Gibson 
(retired CDC), Sue Etkind (Stop TB USA), and 
Sarah Burkholder (Indiana). We thank them for 
their careful review and their diligence. The 
judges gave two awards this year, first place and 
runner-up.  
 
The runner-up in the poster competition: 
Implementation of the 12-Dose Weekly INH plus 
Rifapentine Regimen for Treatment of LTBI in 
Arkansas: A Preliminary Report on Adverse 
Events. Patil N, Mukasa LN, Karpoff E, Egbe 
XM, Smith N, and Bates JH. 
Arkansas Department of Health 
And the winner of the 2013 NTC outstanding 
poster competition: 
Mobilizing to Increase TB Community Awareness 
and Advocacy. Caballero S, Quintero J, 
Navarro C, and Seaworth B. 
Heartland National TB Center 
 
Congratulations to the winners, and thank you to 
all submitters for sharing your data, experiences, 
and excellent solutions! 
 





Get Ready for the New Health 
Insurance Marketplace 
 
Beginning October 1, millions of Americans will 
have a new way to find affordable health 
coverage — including many free preventive 
services — on the new Health Insurance 
Marketplace. The Marketplace will offer 
Americans a whole new way to shop for health 
insurance to gain greater access to affordable 
services such as physician visits, preventive 
care, hospital stays, and prescriptions. Through 
the same streamlined application process, many 
will find out if they are eligible for Medicaid or the 
Children’s Health Insurance Program (CHIP) at 
the Marketplace. Community health centers and 
other organizations will be funded to help 
consumers navigate the new Marketplace. 
Consumers can learn more about the 
Marketplace now and get ready to enroll by 
visiting HealthCare.gov or the Spanish-language 
site CuidadoDeSalud.gov or by calling the new 
24-hours-a-day consumer call center at 1-800-
318-2596. Hearing impaired callers using 
TTY/TDD technology can call 1-855-889-4325 for 
assistance. 
 




CLINICAL RESEARCH BRANCH 
UPDATES 
 
TBTC Semi-Annual Meeting 
 
The Tuberculosis Trials Consortium (TBTC) held 
its 33rd semi-annual meeting on May 14–16 in 
Decatur, GA. Exciting scientific advances and 
developments for TB control were presented. 
The consortium continues to develop its 
longstanding collegiality, collaboration, and high-
value productivity, in support of its mission “to 
conduct programmatically relevant clinical, 
laboratory, and epidemiologic research 
concerning the diagnosis, clinical management, 
treatment, and prevention of tuberculosis 
infection and disease.”  
 
Dr. Robert Belknap of Denver Public Health, 
protocol chair, presented progress in TBTC 
Study 33, “iAdhere,” a phase 4, open label 
randomized clinical trial of delivery modes for the 
12-dose, 3-month regimen of INH and rifapentine 
(3HP) for treatment of latent TB infection (LTBI). 
TBTC Study 26 (Sterling, NEJM 2011; 365:2155) 
demonstrated that 3HP, by directly observed 
therapy (DOT), “was as effective as 9 months of 
isoniazid alone in preventing tuberculosis and 
had a higher treatment-completion rate.” CDC 
(MMWR 2011 60:1650) also recommended 3HP 
by DOT “as an equal alternative to 9 months of 
daily self-supervised INH for treating LTBI in 
otherwise healthy patients aged >12 years...” The 
first question TB program directors often ask is 
whether 3HP can be given safely and effectively 
by self-administered therapy (SAT). Study 33 will 
help answer this question with the TBTC’s 
meticulous evaluation of 1000 participants with 
LTBI, randomized equally into treatment by 1) 
DOT, 2) standard SAT, or 3) SAT enhanced with 
weekly text message reminders. As of May 15 for 
the NTCA report, a total of 439 participants had 
been enrolled at 11 TBTC sites (487 by July 9, 
2013); complete enrollment is expected in the 
first quarter of 2014. 
 
Dr. Susan Dorman of Johns Hopkins University 
and Dr. Rada Savic of the University of California 
at San Francisco presented very encouraging, 
almost uniformly positive findings from TBTC 
Study 29x, a phase 2, double-blind evaluation of 
the safety, tolerability, and efficacy of increasing 
doses of daily rifapentine, administered in place 
of rifampin, in otherwise standard induction 
phase treatment of pulmonary TB. Preliminary 
findings were presented at the May 2013 
international conference of the American 
Thoracic Society (ATS). Study 29x enrolled and 
treated 334 participants at 18 TBTC sites. In a 
pharmacokinetic analysis, the researchers found 
that a single high absolute dose of rifapentine, at 
either 900 mg or 1200 mg daily, rather than more 
complicated weight-based dosing, best provides 
substantial rifapentine exposure without safety or 
tolerability concerns. Rifapentine arms had 
earlier times to stable culture conversion than 
rifampin on solid and in liquid media. 
Interestingly, among patients with cavitary 
disease, the rifapentine arms had substantially 
improved time to conversion in liquid media when 
compared to rifampin.  
 
Many of those in attendance at the meeting are 
hopeful that the next TBTC study will transform 
TB treatment globally by demonstrating the 
safety, tolerability, and effectiveness of a 3- or 4-
month treatment regimen. Current standard 
treatment of drug-susceptible TB requires at least 
6 months; finding shorter treatment regimens is 
one of the greatest immediate needs of 
programmatic TB control and elimination. Based 
on Study 29x findings, the consortium is writing 
TBTC Study 31, Rifapentine-containing 
treatment-shortening regimens for pulmonary 
tuberculosis: A randomized, open-label, 
controlled phase 3 clinical trial. In preparation for 
this important treatment-shortening trial, the 
consortium is conducting 1) data management 
enhancements using FDA-preferred standards 
(CDISC), 2) standardizing and incorporating new 
methods in laboratory practices, 3) optimizing 
retention practices for study participants during 




phase-3 follow-up, and 4) enhancing and 
practicing assessments for disease relapse.  
 
Collaborating attendees at the meeting included 
representatives from NIAID (Dr. Richard Haffner, 
Dr. Barbara Laughon), from the TB Alliance (Dr. 
Stephen Murray), from ACTG (Dr. Sue Swindells, 
Dr. Janet Anderson), from the Otsuka Novel 
Products TB team (Dr. Jeff Hafkin), from Sanofi 
(Isabelle Cieren-Puiseux, Dr. Marilyn Maroni, and 
Dr. Cathy Canteloube), and from Treatment 
Action Group (TAG) (Erica Lessem and Mike 
Frick), in addition to investigators and 
coordinators from TBTC clinical sites.  
Community Research Advisory Group (CRAG) 
members also participated actively. 
 
The TBTC’s contributions to improved treatment 
of TB infection and disease in the United States 
and globally are made possible by the 
tremendous dedication and hard work of staff at 
participating clinical and support sites and at the 
Data and Coordinating Center at the Division of 
TB Elimination in Atlanta. 
 
—Reported by members of the TBTC Data and 
Coordinating Center  
First Meeting of Uganda’s 
Community Advisory Board (CAB) 
 
In 1993, the CDC established the Tuberculosis 
Trials Consortium (TBTC) for the purpose of 
conducting clinical trials of new drugs and 
regimens for the treatment and prevention of 
tuberculosis. The Tuberculosis Trials Consortium 
is comprised of investigators from 19 clinical 
research sites including US academic 
institutions, County Health Departments, and VA 
Medical Centers both domestic and 
internationally. The TBTC has been globally 
recognized as one of the leading TB clinical 
research groups in the world whose consortium 
conducts trials that are programmatically 
relevant. 
 
The Community Research Advisory Group 
(CRAG) has been a vital and growing component 
of the Tuberculosis Trials Consortium (TBTC) for 
several years, partly supported and mentored by 
the Treatment Action Group (TAG). CRAG has 
contributed to evaluation of the TBTC’s informed 
consent process and other activities. At the 
recent TBTC meeting in Atlanta, Dorothy 
Namutamba (CRAG co-chair) described how she 
organized and operationalized the first meeting of 
the Kampala, Uganda, Community Advisory 
Board (CAB), which was attended by TBTC site 
coordinators and other non-TBTC research 
coordinators in Kampala. This initial meeting 
provided an opportunity to introduce the concepts 
of community advisory boards and community 
engagement to study coordinators. The session 
generated a rich discussion, as well as the 
opportunity to hear research priorities from the 
community perspective. 
 
The Kampala CAB’s next steps will include 
building the capacity of the CAB; participants 
decided that future CAB meetings should include 
educative sessions where TBTC members can 
give presentations on TB and TB research. To 
raise awareness about the TB research that is 
taking place in Uganda, Dorothy wrote an article 
published in New Vision, Uganda’s leading daily 
newspaper, on the need for TB research and 
how this can aid some of the programmatic 




—Reported by Beverly DeVoe-Payton and 
Stefan Goldberg, MD, 
Div of TB Elimination, and 
Dorothy Namutamba, Co-Chair of CRAG 
 









DTBE Staff Assist WHO in Training-
of-Trainers Workshop 
 
Wanda Walton, PhD, and Cheryl Tryon, MS, of 
DTBE’s Communications, Education, and 
Behavioral Studies Branch (CEBSB) assisted the 
World Health Organization (WHO) Stop TB 
Department in organizing and implementing a 
Training of Trainers workshop for the 
Programmatic Management of Drug Resistant TB 
(PMDT). The workshop was held in conjunction 
with the WHO Western Pacific Region Office 
(WPRO) in Manila, Philippines, from May 30 to 
June 7, 2013. The overall objective of the 
workshop was to create a pool of master trainers 
in the region who will be able deliver high-quality 
training in their own countries for health care 
workers responsible for implementing services to 
diagnose and treat multidrug-resistant (MDR) TB. 
 
The training was based on MDR TB technical 
modules developed by WHO, using the CDC 
Teachback Methodology Curriculum to develop 
training skills for the participants. The 17 
participants included representatives of national 
TB programs, WHO country offices, and non-
government organizations from the Philippines, 
Vietnam, Cambodia, Mongolia, and China who 
are active in providing TB-related training. Each 
participant developed a country-specific human 
resource development plan for PMDT 
requirements in their own country, and each is 
expected to follow up with implementation of the 
plan after the workshop. 
 
—Reported by Wanda Walton, PhD, and 
Cheryl Tryon, MS 
Div of TB Elimination 
 
The Latent TB Infection (LTBI) 
Treatment Fact Sheet Series – in 
Spanish 
Earlier this year, CDC created the Latent TB 
Infection (LTBI) Treatment Fact Sheet Series. 
Designed to complement the treatment 
counseling delivered by a provider, the series 
consists of fact sheets for each of the three CDC-
recommended LTBI regimens. Each fact sheet 
provides patients with a written reminder of their 
treatment regimen schedule, expected side 
effects, symptoms indicative of a possible 
adverse event, actions to take if symptoms of a 
possible adverse event do occur, tips to help 
remain adherent to the medication, and 
instructions in the event a dose of medication is 
missed. Each fact sheet in the series can be 
personalized for a patient.  
 
Since these medications have rare but potentially 
serious side effects, each fact sheet features a 
prominent red STOP sign. The Isoniazid and 
Rifampin factsheets include a message 
instructing the patient to stop treatment and 
contact the TB doctor or nurse if any problems 
develop. The instruction for symptoms on the 
Isoniazid and Rifapentine (3HP) fact sheet is to 
stop and contact the doctor or nurse without 




waiting for the next scheduled DOT or clinic 
encounter. 
 
After receiving multiple requests to have the 
series translated into Spanish, we are happy to 
announce the Spanish versions are now 
available!  
 
To access the three fact sheets on the CDC 
DTBE website, please visit the TB Publications 
and Products – Factsheet page, under the title 
“What You Need to Know About Your Medicine 




In the upper right hand corner of the page, there 
is a box that will link you to the Spanish version 
of the page. Click your mouse over the words 
“Español (Spanish).” 
 




The link for each fact sheet is also provided 
below.  
 





















The English and Spanish versions of the 
factsheets are also available as Word 
Documents upon request. 
 
Please contact Joan Mangan at bpy4@cdc.gov 
for any comments or more information. 
 
—Submitted by Joan Mangan, PhD, MST, 
Kimberley N Chapman, MPH, CHES, and 
Gloria Oramasionwu, MD, MPH 
Div of TB Elimination 
 
Update on TB Personal Stories 
Project 
 
In the last issue of TB Notes, the TB Personal 
Stories project was described. This project 
supports the goal of raising awareness about TB 
in the United States. Specific objectives include 
communicating the following key points: 
 
• TB still exists and it poses serious health 
consequences if not controlled, 
• Real people still get TB every day and have 
been helped with treatment, and 
• Most importantly, public health provides the 
critical support that TB patients need in order 
to be diagnosed and cured of TB. 
 
By the time of the 2013 World TB Day 
observance, the project had produced the 
following results: 
 
• Eight TB personal stories were posted to the 
TB website. 
• The TB story of one patient, Kenni, was 
posted as a CDC.gov feature the week of 
March 18. 
• On March 22, a pilot video montage in which 
three former TB or LTBI patients told their 
stories debuted at CDC’s World TB Day 
observance. 
 




We are pleased to report that the original pilot 
video montage has been edited based on 
audience feedback. In addition, the individual 
stories of the TB or LTBI patients have been 
made into three short, stand-alone videos. When 
finalized, these videos will be available on the 
DTBE TB Personal Stories web page: 
http://www.cdc.gov/tb/topic/basics/personalstorie
s.htm. Please check back periodically on their 
status; we will also announce when they are 
available. When posted, we hope you will take a 
look at the interesting stories of these three 
individuals as they share their TB experiences 
and what they want others to know about TB. 
The videotape of the entire March 22, 2013, 
World TB Day observance has been posted to 
the DTBE website. Please go to the DTBE World 
TB Day web page at 
http://wwwlink.cdc.gov/tb/events/WorldTBDay/ob
servance.htm to watch the video. 
 
If you know of a former or current TB patient who 
you think would be good for this project, please 
ask him or her to contact Nicole Richardson-
Smith at ewo0@cdc.gov or Ann Lanner at 
lah1@cdc.gov. The ideal candidate would be an 
adult (18 or over) patient who was successfully 
detected, treated, and cured of TB, and who 
would be- 
 
• Willing to appear in a print or video story that 
could be seen by many people, 
• A good candidate for videotaping – is 
articulate and has a compelling story to tell, 
• Willing and able to travel to Atlanta, if 
possible, to be videotaped. Please note that 
a print story and photo for the web would not 
require travel. 
 
—Reported by Ann Lanner and 
Nicole Richardson-Smith, MA 





Federal TB Task Force Diagnostics 
Workgroup Report 
 
The Federal TB Task Force Diagnostics 
Workgroup has made substantial progress in 
several areas. These include Food and Drug 
Administration (FDA) policy efforts aimed at 
improving commercial interest in the 
development of devices that detect M. 
tuberculosis and related drug resistance. Various 
activities are coming together to make this 
happen. For example, progress was reported on 
the establishment of an FDA and National 
Institutes of Health (NIH) co-sponsored Frozen 
Trial Initiative; joint CDC-NIH activity on 
improving the testing for pyrazinamide (PZA) 
resistance; the NIH-sponsored TB Diagnostics 
Research Forum; and CDC and NIH coordination 
on moving from research to international field 
tests for the molecular detection of drug 
resistance.  
 
In March 2012, draft guidance regarding 
reclassification of nucleic acid TB diagnostic 
assays was published. Although reclassification 
was affected by passage of the July 2012 FDA 
Safety and Innovation Act (FDASIA) policy, 
progress continues to move forward with 
reclassification in the context of the new law. On 
June 19, 2013, the FDA published a Special 
Controls document asking for public comment 
within the next 90 days. This document provides 
guidance to manufactures to make TB diagnostic 
tests. 
 
Because of the importance of biomarkers for TB 
treatment efficacy, the FDA and NIH are 
sponsoring a storage bank of clinical trial frozen 
specimens (Frozen Trial Initiative) to aid in 
biomarker discovery. The Consortium for TB 
Biomarkers currently consists of the TB Alliance, 
the AIDS Clinical Trial Group, and the TB Trials 
Consortium. Efforts are underway to store 




prospectively collected specimens from TB 
clinical trials.  
 
Similarly, the workgroup is involved in several 
activities between U.S. agencies and other 
partners. Much of this activity has focused 
around improving the accuracy of diagnosis of 
PZA resistance, because of its important role in 
both current and future TB drug regimens. There 
are several ongoing efforts, which include 
improving PZA testing, improving our 
understanding of pncA mutations and their role in 
PZA resistance, enlarging the database of PZA 
resistant isolates, and promoting cooperation 
between developers of new molecular 
diagnostics and the TB drug development field. 
Future priorities of the workgroup include 
understanding molecular markers for resistance 
of other important drugs besides PZA (e.g., 
fluoroquinolones and new drugs) for drug-
susceptible and drug-resistant TB. They also 
include improved platforms for rapid resistance 
testing for drugs other than rifampin, the use of 
molecular detection of drug resistance for drug 
resistance surveillance, standardization of 
laboratory processes for clinical trials, and 
pediatric diagnostics. 
The Xpert MTB/RIF rollout globally is being 
addressed largely by the International Workgroup 
of the Federal TB Task Force. 
—Reported by Michael F. Iademarco, MD, MPH 
Div of TB Elimination 
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Sandy Althomsons is participating in a 3-month 
detail in South Sudan with the Doctors Without 
Borders organization. She’ll be living in a tent 
and working on an outbreak of Hepatitis E 
amongst the refugee population living in Maban 
county. Hepatitis E is a disease that exists in 
many countries where people live in crowded 
areas with unhygienic conditions. Sandy’s role 
will be to provide epidemiological support to the 
mission in general and, in particular, with a focus 
on supporting the present epidemiologist in the 
response. We wish Sandy the best on this 
endeavor and look forward to her safe and 
healthy return in early September. 
 
Sara Auld, MD, has accepted a position as a 
post-doctoral fellow in Pulmonary and Critical 
Care Medicine at Emory University, and her last 
day here was June 17. In her new role, Sara will 
have the chance to apply the skills she acquired 
and refined through her medical and EIS training 
to pulmonary clinical medicine and research. 
Sara will spend her first year in clinical training, 




and then will join the Division of Pulmonary, 
Allergy, and Critical Care Medicine as an 
investigator on an NIH-funded training grant to 
pursue her research interests. Sara's initial 
surveillance project evaluated and compared an 
integrated surveillance system for TB and HIV as 
well as independent TB and HIV surveillance 
systems used in South Africa. The findings were 
presented to local stakeholders, and used to 
inform the integration of TB and HIV information 
systems and the provision of TB and HIV 
services to persons in the country. She also 
presented the findings at the 43rd World Union 
Congress on Lung Health in Kuala Lumpur, 
Malaysia, in 2012. 
 
Sara also led an Epi-Aid investigating a TB 
outbreak in a group home in Puerto Rico, and 
provided guidance for providing ongoing TB 
education and routine screening for persons 
associated with and considered for admission to 
the group home. Results from this investigation 
that Sara and members of the Surveillance Team 
conducted were published in MMWR (October 5, 
2012). 
 
Sara worked with the Cambodian National TB 
Program to develop algorithms for TB screening 
among persons living with HIV/AIDS and for 
multidrug-resistant TB; as part of this effort, she 
also developed training materials for TB 
managers focusing on TB diagnosis. Sara also 
worked with other CDC divisions and colleagues 
in Cambodia to determine the potential impact of 
screening for TB among persons hospitalized 
with severe acute respiratory infection. This 
analysis, nearing completion, will help determine 
the potential role of introducing active TB case 
finding more broadly among acutely ill, 
hospitalized patients. 
 
Sara also designed, developed, and carried out 
an analysis of US National TB Surveillance 
System data to examine the association between 
tuberculin skin test (TST) results and clinical 
characteristics among persons with culture-
confirmed TB disease. It was found that TST 
results may be a marker of clinical site of 
disease; this suggests that TST may not only 
serve as a marker of infection but may be 
relevant to the pathophysiology and clinical 
presentation of active disease, even among 
persons without overt immune dysfunction (e.g., 
persons without HIV). These results suggest that 
broader incorporation of TST in TB trials and 
prospective analyses may help us better 
understand the relationship between the immune 
system and Mycobacterium tuberculosis. Sara 
presented these findings at the EIS conference in 
2013, and she is the lead author on the 
manuscript that has been submitted for 
publication in a peer-reviewed medical journal. 
 
Bruce Bradley, MPA, Senior Public Health 
Advisor (PHA), was assigned to the Georgia TB 
Control Program on June 3, 2013, where he will 
serve as PHA to the state program. Bruce started 
his career with CDC/DTBE in 2002 as a Public 
Health Analyst in the Data Management and 
Statistics Branch; in addition, he served as the 
Technical Contact for the CITS II contract and 
the TIMS trainer. He was one of the TB subject 
matter experts for the development and design of 
the NBS TB PAM and the eRVCT.  In addition, 
he was instrumental in assisting national TB 
programs with the transition from TIMS to 
NEDSS. Bruce served from 1993-1997 as a 
regional TB program coordinator in the state of 
Georgia. In July 2009, Bruce accepted the 
position with FSEB as the TB Program Manager 
for Fulton County, Georgia. In his position he 
managed the TB Program and helped lead the 
screening of homeless shelters in Fulton County. 
He was instrumental in helping to implement the 
3HP treatment for LTBI in the county and to 
improve the LTBI completion rate. He also 
served as co-project coordinator for other CDC 
funded initiatives and projects (House Ball 
Community). Bruce holds a Master of Public 
Administration degree from Georgia College and 
State University and is the recipient of a 
Graduate Certificate in Epidemiology from the 
Tulane School of Public Health and Tropical 




Medicine. He is a candidate for a Masters of 
Public Health from Georgia State University. 
 
Deron Burton, MD, has joined the TB/HIV Team 
of the International Research and Programs 
Branch within the Division of TB Elimination. 
Deron will be serving as the Lead for Pediatric 
TB and TB/HIV for IRPB.  Deron comes to IRPB 
having most recently served as a Medical 
Epidemiologist and as the Deputy Director for 
Science for CDC's International Emerging 
Infections Program, Division of Global Disease 
Detection and Emergency Response, Center for 
Global Health in Nairobi, Kenya. Deron joined 
CDC in 2004 as an Epidemic Intelligence Service 
(EIS) Officer with the Respiratory Disease 
Branch. He holds degrees in law, medicine, and 
Public Health and we are excited about adding 
his broad training and experience to improve our 
capacity to integrate policy, science, and Public 
Health practice. 
 
Alyssa Finlay, MD, has joined DTBE/IRPB as the 
Director for the TB/HIV Research Division at 
CDC Botswana. Alyssa most recently served as 
the CDC Madagascar Country Representative 
and Malaria Advisor for the President's Malaria 
Initiative, Malaria Branch, Division of Parasitic 
Diseases and Malaria from 2008-2013. Alyssa 
joined CDC in 2003 as an Epidemic Intelligence 
Service (EIS) Officer with IRPB/DTBE. She 
worked with IRPB for 5 years as an EIS officer, 
medical officer and later as the TB/HIV Team 
Lead. Alyssa holds degrees in chemical 
engineering and medicine. Alyssa and her 
husband arrived at post in Botswana on June 9, 
2013. 
 
Juliana Grant, MD, who has been with SEOIB for 
4 years and Lead of Molecular Epidemiology for 
3 years, has left DTBE for an exciting job as 
manager of the Division of HIV/AIDS 
Prevention’s (DHAP) HIV/AIDS surveillance 
program in the California Department of Public 
Health. Under her leadership, TB Genotyping 
Information Management system (GIMS) has 
flourished and early outbreak detection has 
become a reality. She spearheaded an ambitious 
yet realistic strategic plan as the Lead for the 
Molecular Epidemiology Activity (MEA). Her deft 
leadership enabled SEOIB to smoothly transition 
activities funded by Aberration Detection TB 
Leads funding to core work of the branch. She 
convened end users and key stakeholders from 
local, state, and national levels to form the 
Outbreak Detection Working Group and expand 
outbreak detection efforts. She and her team 
have been recognized as NCHHSTP, CDC, and 
private industry honors award recipients for TB 
GIMS. During her time with SEOIB, Dr. Grant has 
served in the field to investigate TB clusters, 
responded to oil spill relief efforts, served in the 
EOC numerous times, and juggled her 
responsibilities as the MEA Lead while assisting 
the Outbreak Investigations Team during critical 
outbreak investigations. DTBE will be losing a 
valued and irreplaceable colleague. Dr. Grant’s 
last day in SEOIB before heading out to 
Sacramento was June 27. 
 
Rickenya Hodge, Resource Management 
Specialist/OD, is the worthy recipient of the 
DTBE Director’s Recognition Award for the third 
quarter of 2013. Rickenya was nominated for her 
work in coordinating Division funding actions, 
providing excellent customer service, and 
supporting the DTBE ADMO amidst the 
budgetary turmoil of FY13. Rickenya joined 
DTBE less than 2 years ago, and quickly became 
familiar with the Division’s multiple, large and 
complex contractual and cooperative 
agreements. Because of her outstanding 
organizational and communication skills, she 
helps ensure that DTBE submits funding 
packages that are complete, error-free, and on-
time. She takes the lead on coordinating the 
Division’s responses to multiple, quick-
turnaround requests for funding data, and 
produces reports that are concise and easily 
understood. She routinely puts in late hours and 
comes in on her telework days in order to get the 
job done. In addition to her exceptional technical 
skills, Rickenya has an unfailingly positive 
attitude and excels at customer service. In her 




relatively short time with the Division, she has 
developed effective working relationships with 
staff from across the Division, as well as 
colleagues at the NCHHSTP, PGO, and FMO 
levels. Internal and external customers regularly 
comment on her responsiveness and reliability. 
Her assistance to the DTBE ADMO has been 
invaluable during one of the most challenging 
fiscal years in recent memory. Amidst ever-
changing budgetary targets, Rickenya revised 
and re-revised projections to keep DTBE within 
budget. She approaches her work with an eye 
toward continual improvement of both process 
and quality.  
 
Meredith Howley, MS, has accepted a promotion 
with at the National Center for Environmental 
Health/Agency for Toxic Substances and 
Disease Registry, Office of Science after almost 
4 years with SEOIB’s Epidemiology Team. 
During her time with the Epi Team, Meredith did 
an outstanding job of helping develop the 
protocol for the Tuberculosis Epidemiologic 
Studies Consortium (TBESC) core study, Task 
Order (TO) 1. In addition to working on the 
protocol for TO 1, Meredith played a major role in 
the development of the Data Collection Forms 
and the Data Management System for the study. 
Also, Meredith was the project coordinator for TO 
31 (Evaluation of Interferon Gamma Release 
Assays in Overseas Immigration Examination of 
Children in Moderate and High-Burden 
Countries) and TO 32 (the Current Cost of TB 
within Urban United States). Currently, she is 
writing the manuscript describing TO 31 findings. 
The Epi Team will miss her, and we wish her well 
in her new job. 
 
Jimmy Keller, MA, DHSc, has transferred from 
the Florida State TB Program in Tallahassee as a 
Senior Public Health Advisor to the New York 
City TB Program effective June 2, 2013. In his 
new role, Jimmy will be assisting the program 
with strategic planning and program evaluation. 
He started his career with CDC in 1991 as a 
Public Health Associate – Disease Intervention 
Specialist with the Miami-Dade County Health 
Department STD Program in Florida. In 1992, he 
was transferred to the NYC Department of Health 
STD program, and in 1995, he joined the CDC 
DTBE and was assigned to the NYC TB Control 
Program. Since then, Jimmy has held several 
other positions within DTBE in Detroit MI, 
Columbus OH, Raleigh NC, and Tallahassee Fl. 
He holds several degrees, including a BS, MA, 
and DHSc. 
 
Terry Lo, DrPH, has accepted a position as an 
Epidemiologist with the Prevention of Mother to 
Child Transmission (PMTCT) team within the 
Division of Global HIV and AIDS. In his new 
position, Terry will be working on projects in sub-
Saharan and southern Africa. His last day here 
was July 1. As part of the TB/HIV team in IRPB, 
Terry evaluated the multidrug resistance (MDR) 
surveillance system in Thailand and identified 
opportunities to improve the quality and 
timeliness of reported data. He mentored TB 
controllers during multiple operations research 
courses which he taught in both India and 
Uganda. Also, along with members of the 
Surveillance Team, Terry authored the 2013 
National Trends in Tuberculosis MMWR report; 
Terry presented data from that report at the 2013 
CDC World TB Day observance on March 22. He 
also published a manuscript describing the 
prevalence of alcohol abuse and tobacco 
smoking in rural Western Kenya. Terry also led 
two Epi-Aids including a national evaluation of TB 
case finding activities in South Africa and a TB 
outbreak investigation among persons 
associated with the illegal transportation and 
distribution of moonshine in rural Kentucky. Terry 
is a graduate of UCSD, the Rollins School of 
Public Health at Emory, and the University of 
California, Berkeley. Terry has previously worked 
with the California state department of public 
health, STOP Polio, and World Health Partners in 
India. Terry contributed greatly to DTBE's and 
IRPB's mission, and though the Division is sad to 
see him leave, we look forward to collaborating 
with him as a colleague in DGHA.  
 




Melissa Pagaoa is leaving the Epidemiology 
Team, Surveillance Epidemiology and Outbreak 
Investigations Branch (SEIOB), DTBE, for a 
promotion into a new position at the Office of the 
Public Health Preparedness and Response 
(OPHPR), Division of State & Local Readiness 
(DSLR). In her 4 years with us, Melissa oversaw 
the collection and management of data for 
Tuberculosis Epidemiologic Studies Consortium 
(TBESC) Task Order 23, which seeks to identify 
factors associated with timely diagnosis of TB in 
US-born African Americans and whites. She has 
been the lead analyst for two manuscripts on this 
research study. Melissa also worked on Task 
Order 30, quantifying the risk of premature death 
in TB survivors. In addition, she played a major 
role in the implementation of the new TBESC 
core study, Task Order 1. We appreciate and 
celebrate Melissa’s many contributions to TBESC 
and the Epidemiology Team/SEIOB.  We will 
miss her, but we wish her the best in her new job. 
June 14 was her last day in DTBE. 
 
Angel Roca transferred from the New York City 
TB Program as a Senior Public Health Advisor to 
the headquarters of CDC’s DTBE in Atlanta 
effective June 2, 2013. Angel started his career 
in public health in 1980 as a Public Health 
Advisor VD investigator with the Onondaga 
County Health Department in Syracuse, New 
York and a year later with the New York State 
Department of Health. He first joined CDC in the 
National Center for Chronic Disease Prevention 
and Health Promotion (NCCHPHP) as a project 
officer for the Division of Adolescent and School 
Health in April 1992. In 1993, he moved to the 
Center’s Office of the Director to serve as the 
HIV Liaison, under the matrix management of 
HIV activities at CDC. In 1996, he was promoted 
to the Deputy Director of Planning, Evaluation, 
and Legislation. In 2001, he was transferred to 
NCCDPHP’s Global Health Promotion where he 
served as the Deputy Associate Director, working 
with Ministries of Health to promote non-
communicable disease prevention and control, 
and health promotion activities. In 2007, Angel 
was assigned to the CDC Regional Office for 
Central America and Panama (CDC-CAP) in 
Guatemala City, Guatemala, where he served as 
Deputy Director/Overseas Business Manager. In 
2009, he returned stateside as the Team Lead 
for the Training and Staff Development Team, 
Workforce Management Office, Center for Global 
Health. In 2010, he joined DTBE and was 
assigned to New York City as Deputy Director for 
the NYC TB program. Mr. Roca holds a BA in 
Public Justice, and is working on an MPH at the 
Emory School of Public Health. 
 
James Shepherd, MD, is now with DTBE/IRPB 
as the in-country CDC Medical Officer, detailed 
to the WHO India Country Office. He will serve as 
a senior TB advisor and provide technical 
assistance to the Government of India's Revised 
National TB Control Program. As many of you 
know, James most recently served as the 
Associate Director for TB at the Botswana USA 
collaboration (BOTUSA) in the CDC Botswana 
Office in Gaborone October 2009 to May 2013. 
 
Padmaja Vempaty, MPH, has accepted a 
promotion as health scientist at the National 
Center for Environmental Health/Agency for 
Toxic Substances and Disease Registry after 6 
years with SEOIB’s Epidemiology Team. During 
her time as a project coordinator for the 
Tuberculosis Epidemiologic Studies Consortium 
(TBESC), Padmaja had major roles in the 
implementation, data management, and data 
analysis for two large studies in the first TBESC. 
Task Order 13 investigated factors associated 
with acceptance and adherence with and toxicity 
from treatment for latent TB infection. Task Order 
26 evaluated a new method for prioritizing TB 
genotype cluster investigations and assessed the 
cost-effectiveness of conducting those 
investigations. In the new TBESC, Padmaja was 
the consortium’s Institutional Review Board (IRB) 
coordinator. She also worked on the consortium’s 
biobanking initiative and the evaluation of the 
relative cost-effectiveness of tests for latent TB 
infection (LTBI). We will miss her, and wish her 
all the best in her future endeavors. 
 






Bertrand W. Russell, former CDC TB public 
health advisor, passed away on May 17, 2013. 
He was born in 1934 in Louisville, Kentucky. He 
is survived by his wife of 32 years, Kathleen 
Russell, and a large extended family. Bert was a 
member of St. Paul's Catholic Church in 
Jacksonville Beach, St. Vincent DePaul Society, 
and a volunteer for Northeast Community 
Hospice. He served 10 years in the Medical 
Division of the Kentucky Air National Guard. 
 
After graduating from Bellarmine College in 1957, 
he began a 30-year career with CDC. He was a 
Public Health Advisor to the tuberculosis control 
programs in Tennessee and Florida. After retiring 
from CDC, he worked 11 years for the Duval 
County Florida Health Department where he was 
manager of the Epidemiology Program and later, 
manager of the Beaches Family Health Center. 
 
Bert loved going home to Louisville with his wife 
each year to attend the Kentucky Derby. He was 
commissioned as a Kentucky Colonel by 
Kentucky Governor Bert Combs in 1963. He was 
a member of the Jacksonville, Florida, Track 
Club and for 20 years was an age-group 
competitor in numerous local, state, and national 
runs and triathlons, including the Boston 
Marathon and an International Triathlon in 
Southern France. 
 
A Mass of Christian Burial was celebrated on 
May 22 in St. Paul's Catholic Church, 
Jacksonville Beach, Florida. On May 24, a 
memorial service was held in Kentucky, followed 
by interment in the St. Aloysius Cemetery in 
Kentucky. In lieu of flowers, the family would 
appreciate donations be made to St. Vincent 
DePaul Society, in care of St. Paul's Catholic 




Louis Salinas, MPA, who 
served for 22 years as a 
CDC TB public health 
advisor, died on July 13, 
2013. He had retired 
from CDC in August 
2010 after a 
distinguished career in 
public health. In his last 
position with CDC, Louis 
served as Deputy 
Director of the Division of 
Oral Health, National Center for Chronic Disease 
Prevention and Health Promotion. 
 
Louis, who earned his undergraduate degree 
from the University of Texas-Austin and holds a 
master’s degree in Public Administration from 
California State University-Long Beach, joined 
CDC in 1974 as a public health advisor. His initial 
field assignment was San Antonio, Texas. He 
was subsequently assigned to Miami, FL, San 
Juan, Puerto Rico, and Los Angeles, CA. In 
January 1986, he transferred to CDC 
headquarters where he served as a Program 
Consultant for the Division of Tuberculosis 
Elimination. His most notable experience during 
this assignment was as principal liaison to New 
York City and New York State health 
departments at the height of their TB and 
multidrug-resistant TB crisis in the early 1990s. 
While in DTBE, Louis helped to establish several 
U.S.-Mexico binational TB programs to improve 
TB case detection and the continuity of care of 
these persons. During this period he also had 
three special assignments, one with the Office of 
Foreign Disaster Assistance in Angola and two 
with the World Health Organization (WHO) to 
Brazil and Mexico. 
 
From 1996 through 1998, he served as the Chief 
of the Program Coordination Unit, National 
Center for HIV, STD, and TB Prevention, an 
activity designed to evaluate the feasibility of 
having cross divisional project officers for the 
STD, TB, and HIV programs. From 1998 to 2000, 
he was assigned as the principal liaison to the 




United States Agency for International 
Development (USAID) in Washington. In that 
capacity he provided technical assistance to 
USAID and USAID missions on global TB issues 
and the relation to HIV/AIDS, focusing primarily 
on the Russian Federation, the Newly 
Independent States (of the former Soviet Union), 
Ukraine, Romania, Moldova, Kosovo, and 
Mexico. He also worked as a Country Support 
Coordinator with CDC’s Global AIDS Program 
with responsibility for Ethiopia, Cote d' Ivoire, 
Kenya, Malawi, Mozambique, Nigeria, and 
Uganda.  
 
In October 2000, he joined the National Center 
for Chronic Disease Prevention and Health 
Promotion’s Division of Reproductive Health, 
where he initially served as Deputy Branch Chief 
and later as the Associate Director for 
Management and Operations before becoming 
the Acting Deputy Division Director. 
In June 2003, he became the Deputy Director for 
the Division of International Health for CDC’s 
Epidemiology Program Office (EPO). In February 
2004, he rejoined the Chronic Disease Center as 
Deputy Director for the Division of Adolescent 
and School Health. 
 
Then, in May 2008, he was named Deputy 
Director of the Division of Oral Health. In May 
2009, he was requested by CDC’s Director, 
Thomas Frieden, to serve as the agency’s Acting 
Chief of Staff, where he was responsible for 
managing day-to-day operations of the Office of 
the Director, helping to resolve issues that 
crossed organizational lines, determining policy 
and program objectives, coordinating decision-
making processes, and maintaining a focus on 
the highest priority initiatives. In May 2010, he 
returned to the Deputy Director position within 
the Division of Oral Health. In August 2010, he 
retired from CDC, and continued to share his 
public health expertise in retirement as a 
consultant. 
 




CALENDAR OF EVENTS 
 
July 20-23, 2013 
RESULTS International Conference 2013 
Crystal City, Arlington, Virginia  
RESULTS International 
  
August 14-15, 2013 
4th Semi-annual TBESC Meeting 
Atlanta, GA 
TB Epidemiologic Studies Consortium 
  
August 19–21, 2013 
APHL 8th National Conference on Laboratory 
Aspects of Tuberculosis 
San Diego, CA 
www.aphl.org/conferences/pages/default.aspx 
 
September 9, 2013 
6th International Workshop on Clinical 




September 17-20, 2013 
ASTHO Annual Meeting 
Orlando, FL 
Association of State and Territorial Health 
Officers 
  
September 21-24, 2013 
American College of Epidemiology Annual 
Meeting 
Louisville, KY 
American College of Epidemiology 
 
October 9-12, 2013 
Denver TB Course 
Denver, CO 
National Jewish Health 
  
October 14-19, 2013 
Evaluation 2013 
Washington, DC 
American Evaluation Association 
  
October 22, 2013 
Pre-conference scientific seminar prior to 
Southeast TB controllers meeting 
Southeastern National Tuberculosis Center 
 
October 23-25, 2013 
2013 Southeast TB Controllers Meeting 
Savannah, GA 
 
October 29-30, 2013 




October 30-November 3, 2013 
44th UNION World Conference on Lung Health 
Paris, France 
The Union 
 
